IDXX

SEC source: 0001567619-20-015709 · doc1.xml · nonDerivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,933

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-015707 · doc1.xml · derivative · entry 15

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,940 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · price: Not applicable.

F11 · derivative.exercise_date: Grant of option to buy 44,535 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 12

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 810,467

F10 · price: Represents the weighted average price of the shares sold ranging from a low of $384.28 to a high of $385.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 11

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 812,847

F9 · price: Represents the weighted average price of the shares sold ranging from a low of $383.129 to a high of $384.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 10

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 818,550

F8 · price: Represents the weighted average price of the shares sold ranging from a low of $382.099 to a high of $383.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 9

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 830,407

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-015711 · doc1.xml · nonDerivative · entry 2

Hunt Nimrata · CIK 0001800619 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,847

SEC source: 0001567619-20-015711 · doc1.xml · nonDerivative · entry 1

Hunt Nimrata · CIK 0001800619 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,947

F1 · balance_after: Includes a total of 38 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020 and June 30, 2020.

SEC source: 0001567619-20-015712 · doc1.xml · derivative · entry 10

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,098 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · price: Not applicable.

F7 · derivative.exercise_date: Grant of option to buy 18,549 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning February 14, 2015 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-015712 · doc1.xml · derivative · entry 9

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,836 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · price: Not applicable.

F6 · derivative.exercise_date: Grant of option to buy 18,918 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on January 1, 2015 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-015712 · doc1.xml · derivative · entry 8

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,790 shares

Expires 2023-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · price: Not applicable.

F5 · derivative.exercise_date: Grant of option to buy 4,395 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on May 8, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 7

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,596

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $380.792 to a high of $381.79 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 6

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,645

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $379.676 to a high of 380.674 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 5

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,114

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $378.63 to a high of $379.614 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 4

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,323

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $377.49 to a high of $378.43 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 3

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,320

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 2

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-015712 · doc1.xml · nonDerivative · entry 1

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,386

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-015709 · doc1.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304

SEC source: 0001567619-20-015707 · doc1.xml · derivative · entry 14

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,940

Underlying: Common Stock · 25,000 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · price: Not applicable.

F11 · derivative.exercise_date: Grant of option to buy 44,535 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 8

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 810,467

F7 · price: Represents the weighted average price of the shares sold ranging from a low of $384.075 to a high of $384.225 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 6

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 810,923

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $382.51 to a high of $382.721 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 811,051

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $381.29 to a high of $381.845 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 812,928

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $379.87 to a high of $380.66 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 814,744

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $377.49 to a high of $378.43 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 829,167

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $377.49 to a high of $378.43 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 835,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874716-20-000033 · primary_doc.xml · derivative · entry 3

MCKEON BRIAN P · CIK 0001219445 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,481

Underlying: Common Stock · 193 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

F2 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

SEC source: 0000874716-20-000033 · primary_doc.xml · nonDerivative · entry 2

MCKEON BRIAN P · CIK 0001219445 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,596

SEC source: 0000874716-20-000033 · primary_doc.xml · nonDerivative · entry 1

MCKEON BRIAN P · CIK 0001219445 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes a total of 43 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020 and June 30, 2020.

SEC source: 0000874716-20-000032 · primary_doc.xml · derivative · entry 3

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,343

Underlying: Common Stock · 385 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

F2 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020.

SEC source: 0000874716-20-000032 · primary_doc.xml · nonDerivative · entry 2

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,333

SEC source: 0000874716-20-000032 · primary_doc.xml · nonDerivative · entry 1

MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes a total of 45 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020 and June 30, 2020.

SEC source: 0001567619-20-014062 · doc1.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,847

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($4,959.24) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-20-014060 · doc1.xml · nonDerivative · entry 1

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 904

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($15,869.57) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001567619-20-011544 · doc1.xml · derivative · entry 8

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,722 shares

Expires 2025-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: Not applicable.

F6 · derivative.exercise_date: Grant of option to buy 3,861 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one annual installment on May 6, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 6

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · M. Anne Szostak Trust

Disclosed balance after: 0

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $307.72 to a high of $308.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F1 · ownership.nature: The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.

SEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 5

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · M. Anne Szostak Trust

Disclosed balance after: 1,690

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $306.67 to a high of $307.40 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F1 · ownership.nature: The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.

SEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 4

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · M. Anne Szostak Trust

Disclosed balance after: 4,742

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $305.53 to a high of $306.52 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F1 · ownership.nature: The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.

SEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 3

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · M. Anne Szostak Trust

Disclosed balance after: 7,722

F1 · ownership.nature: The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.

SEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 2

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 1

SZOSTAK M ANNE · CIK 0001094176 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,722

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-011545 · doc1.xml · derivative · entry 9

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,256 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · price: Not applicable.

F8 · derivative.exercise_date: Grant of option to buy 628 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2020 without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-011545 · doc1.xml · derivative · entry 8

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,814 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · price: Not applicable.

F7 · derivative.exercise_date: Grant of option to buy 6,407 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001567619-20-011545 · doc1.xml · nonDerivative · entry 7

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,892

F6 · price: Represents the weighted average price of the shares sold ranging from a low of $308.62 to a high of $309.40 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-011545 · doc1.xml · nonDerivative · entry 6

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,759

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $307.60 to a high of $308.41 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-011545 · doc1.xml · nonDerivative · entry 5

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,005

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $306.58 to a high of $307.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-011545 · doc1.xml · nonDerivative · entry 4

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,003

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $305.55 to a high of $306.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-011545 · doc1.xml · nonDerivative · entry 3

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,603

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $304.46 to a high of $304.98 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-011545 · doc1.xml · nonDerivative · entry 2

TWIGGE GIOVANI · CIK 0001500399 · CORPORATE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,962

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.